Kura Oncology raises $50M for diabetes-focused subsidiary Caspian; retains ~49% stake

Kura Oncology, Inc.

Caspian Therapeutics, a new wholly owned subsidiary, raised $50.0M in Series A preferred stock on Sept 8, 2026.
Kura invested $4.3M; post-financing Kura holds ~49.2% of Caspian's outstanding capital stock.
Kura contributed rights to next-gen menin inhibitors for diabetes/cardiometabolic diseases, incl. KO-7246, to Caspian.
Kura granted Caspian non-exclusive licenses to ziftomenib-related patents/data; received reciprocal license for R&D.
Caspian solely responsible for development/regulatory/commercialization in diabetes field; Kura provides services under agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.